MedTrace Logo

The Use of Cannabidiol Suppositories for Sexual Pain

NCT07271030 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-01-26

No results posted yet for this study

Summary

Research aim: To determine how cannabidiol suppositories might reduce sexual pain during intimacy. Outcomes are also hoped to increase sexual functioning, well-being, and quality of life.

Research intention: If cannabidiol suppository intervention reduces sexual pain and increases general well-being, then this research would be repeated on a larger scale, targeting psychosexual services.

A brief overview of the intervention:

Quantitatively, randomisation of cannabidiol suppositories will be into dose-specific groups. The intervention will be delivered over a period of one month, with follow-up scheduled at 12 weeks. Qualitatively, participants were asked approximately eight open-ended feedback questions throughout the study.

Conditions

  • Well-Being, Psychological
  • Quality of Life
  • Sexual Behavior
  • Sexual Pain Disorder

Interventions

DIETARY_SUPPLEMENT

Cannabidiol suppository intervention 1

Cannabidiol suppository dose specific 30mg

DIETARY_SUPPLEMENT

Cannabidiol suppository intervention 2

Cannabidiol suppository dose specific 50mg

DIETARY_SUPPLEMENT

Cannabidiol suppository intervention 3

Cannabidiol suppository dose specific 100mg

OTHER

Non cannabidiol group control

Care as usual group

Sponsors & Collaborators

  • London Metropolitan University

    lead OTHER

Principal Investigators

  • Samantha Banbury · London Metropolitan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-16
Primary Completion
2026-07-31
Completion
2026-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07271030 on ClinicalTrials.gov